pirtobrutinib
E888599
Pirtobrutinib is a highly selective, non-covalent Bruton tyrosine kinase inhibitor used as a targeted therapy for certain B-cell malignancies.
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
Bruton tyrosine kinase inhibitor
ⓘ
non-covalent BTK inhibitor ⓘ small molecule drug ⓘ targeted therapy ⓘ |
| approvedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| binds | BTK in a reversible manner ⓘ |
| developedBy | Eli Lilly and Company NERFINISHED ⓘ |
| hasAdministrationFrequency | once daily ⓘ |
| hasApprovalType | accelerated approval in the United States ⓘ |
| hasATCCode | L01EL04 ⓘ |
| hasCommonAdverseEffect |
anemia
ⓘ
bruising ⓘ cough ⓘ diarrhea ⓘ fatigue ⓘ neutropenia ⓘ pneumonia ⓘ thrombocytopenia ⓘ |
| hasDosageForm | oral tablet ⓘ |
| hasDrugClass |
antineoplastic agent
ⓘ
protein kinase inhibitor ⓘ |
| hasGeneration | next-generation BTK inhibitor ⓘ |
| hasIndicationStatus | for patients previously treated with at least two lines of systemic therapy including a BTK inhibitor in mantle cell lymphoma ⓘ |
| hasMechanismOfAction | BTK inhibition ⓘ |
| hasMolecularTargetClass | tyrosine kinase ⓘ |
| hasPharmacologicClass | BTK inhibitor ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasSelectivity | highly selective for BTK ⓘ |
| hasTarget | Bruton tyrosine kinase NERFINISHED ⓘ |
| hasTherapeuticArea |
hematologic oncology
ⓘ
lymphoid malignancies ⓘ |
| hasTradeName | Jaypirca NERFINISHED ⓘ |
| isActiveAgainst | BTK C481S mutation ⓘ |
| isCovalent | no ⓘ |
| isDesignedToOvercome | resistance to covalent BTK inhibitors ⓘ |
| isNonCovalent | yes ⓘ |
| isSubstrateOf | CYP3A NERFINISHED ⓘ |
| isTakenBy | adult patients ⓘ |
| isUsedFor |
B-cell malignancies
ⓘ
other relapsed or refractory B-cell lymphomas ⓘ relapsed or refractory chronic lymphocytic leukemia ⓘ relapsed or refractory mantle cell lymphoma ⓘ relapsed or refractory small lymphocytic lymphoma ⓘ |
| metabolism | hepatic ⓘ |
| reduces |
B-cell proliferation
ⓘ
survival of malignant B cells ⓘ |
| regulates | B-cell receptor signaling ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.